Novel technologies and emerging biomarkers for personalized cancer immunotherapy
about
Neoantigen-based cancer immunotherapyImmune checkpoint blockade therapy for bladder cancer treatmentCheckpoint Inhibitors and Their Application in Breast CancerCurrent status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapySingle-Cell Genomics for VirologyApproaches to modernize the combination drug development paradigmValidation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validationTumor Microenvironment Metabolism: A New Checkpoint for Anti-Tumor ImmunityAdvances in Cancer Immunotherapy in Solid TumorsRImmPort: an R/Bioconductor package that enables ready-for-analysis immunology research data.Immune Checkpoint Inhibitors: An Innovation in Immunotherapy for the Treatment and Management of Patients with Cancer.Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common ruleCharacterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes.Immunotherapy biomarkers 2016: overcoming the barriers.Systematic evaluation of immune regulation and modulationMonitoring immune responses in the tumor microenvironment.Optimizing tumor immune response through combination of radiation and immunotherapy.Cancer Immunotherapy, Part 3: Challenges and Future Trends.Multiparametric immune profiling in HPV- oral squamous cell cancerCheckpoint inhibitors in advanced melanoma: effect on the field of immunotherapy.Bioprinting and Organ-on-Chip Applications Towards Personalized Medicine for Bone Diseases.Correlation of immune phenotype with IDH mutation in diffuse glioma.Predictive biomarkers for checkpoint inhibitor-based immunotherapy.Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication.Circulating protein and antibody biomarker for personalized cancer immunotherapy.The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer.Checkpoint Inhibitors in Head and Neck Cancer: Rationale, Clinical Activity, and Potential Biomarkers.PD-1/PD-L1 blockade in renal cell cancer.Immuno-Oncology: The Third Paradigm in Early Drug Development.Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy.Secreted tumor antigens - immune biomarkers for diagnosis and therapy.Commentary: A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment.Comprehensive immune transcriptomic analysis in bladder cancer reveals subtype specific immune gene expression patterns of prognostic relevance.Cancer immunotherapy trials: leading a paradigm shift in drug development.CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: diverging prognostic impact in primary tumors and lymph node metastases.Immunotherapy and gene therapy as novel treatments for cancer.From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely.Patent trend and competitive analysis of cancer immunotherapy in the United States.The current status of immunobased therapies for metastatic renal-cell carcinoma.Immune monitoring technology primer: whole exome sequencing for neoantigen discovery and precision oncology.
P2860
Q26738693-9EA489CE-F635-4FBE-B3DA-0223FA5E9A7BQ26744139-8F6E4E43-78E6-4E09-B823-6A738974E033Q26745442-C043AC21-C6DD-41A5-B17B-A5DCFB1324DFQ26745516-C1B30D8C-7C13-4F0A-A958-2990505A8913Q26751486-6E0981D7-DCF1-4AC0-986C-A14150AE6DACQ28072074-E36C0787-BF5F-44E8-8D30-F06684D203F7Q28075719-33D6987C-5651-4EB3-B61F-AF95A8472BA5Q28077647-3E6FFE62-7963-4ED4-A9D8-A16F898157EEQ28080113-26B303C5-5F2F-479F-9219-42BEA7BA9A86Q30490637-1ADF7473-FFDC-410F-BED9-461B0BC8D3B2Q33623877-FEBCD837-A591-4FC7-97E4-6B60FC0019A6Q37024565-F9106190-3042-4A03-AB7B-16AC86DCFA84Q37665652-6C0B6185-2E8C-48F5-AA11-17BE71F53435Q37713438-3C538358-CFC7-48C9-AC38-34C7B6CB7775Q37713498-86C33EC2-AA89-4395-89DC-E7571E56E4EAQ38380080-E7536523-04E4-40A8-BCEC-BFE1B6FC3AC2Q38614781-B3AA0D1A-371B-4818-A636-0CF4A7EA17F2Q38646290-C5E12376-8F2F-4D2F-99A2-5ED014A3E3BDQ38671420-70481A54-4955-4B36-B05B-282988D1F315Q38672084-DD9A9E8E-EB2B-4B1E-9B23-9E6CCA40AFD3Q38673908-449B780D-01A2-47FB-9B53-81B7D4D40435Q38771020-A7B2822D-7E8A-4F9B-8E0B-5A966F1E7E5DQ38786289-3BD606B3-EA3D-4D31-BC79-66FAEEE50D00Q38823649-59492D80-057F-4479-97E0-51F7C2476D7BQ38830620-BCDC9B62-FBB6-4B14-AFAE-61814C3C5E35Q38847321-CD11578C-5FD0-4120-B056-028E46C5C552Q38868396-0FF34AF7-C620-4775-BBB8-71329FEDFA37Q38899769-92571BB4-AD0B-4D52-8F5B-66C3CDE9D133Q39044147-78A39FB8-3CD9-4CDB-81B1-1D5E30CAF07FQ39176046-F43DA3F3-F38B-4B01-9AE1-0E4B2AF2904DQ39438407-E42BCF41-B89E-4478-BB11-18E9E1F222FEQ40985733-7B5C25C6-8D6A-418C-84CF-31C03C28BB73Q42378498-0A405E41-E344-488E-933A-FC2B4F11EF3AQ42414063-DE1D850A-08F0-4784-8A6A-72CF6EFBD2B7Q42683596-772529FA-D9F4-42D6-BF00-F118AE3D04C1Q45875535-6FDA9BE5-8504-42D0-96DD-C185F6000671Q45952214-E3486CB3-5F04-4FB3-BA57-3D5DFBE2BF76Q46310803-5DA551AC-6050-4C98-BEE0-4AABC542A8FCQ47097756-CBCCDA52-650F-427A-AB43-3F54635FE241Q47101602-E2530EC3-6D29-4114-8290-49AA5A857435
P2860
Novel technologies and emerging biomarkers for personalized cancer immunotherapy
description
2016 nî lūn-bûn
@nan
2016 թուականին հրատարակուած գիտական յօդուած
@hyw
2016 թվականին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Novel technologies and emerging biomarkers for personalized cancer immunotherapy
@ast
Novel technologies and emerging biomarkers for personalized cancer immunotherapy
@en
Novel technologies and emerging biomarkers for personalized cancer immunotherapy
@nl
type
label
Novel technologies and emerging biomarkers for personalized cancer immunotherapy
@ast
Novel technologies and emerging biomarkers for personalized cancer immunotherapy
@en
Novel technologies and emerging biomarkers for personalized cancer immunotherapy
@nl
prefLabel
Novel technologies and emerging biomarkers for personalized cancer immunotherapy
@ast
Novel technologies and emerging biomarkers for personalized cancer immunotherapy
@en
Novel technologies and emerging biomarkers for personalized cancer immunotherapy
@nl
P2093
P2860
P3181
P1476
Novel technologies and emerging biomarkers for personalized cancer immunotherapy
@en
P2093
Bernard A Fox
Cristina Maccalli
David B Page
Edward C Stack
Harlan Robins
Heinz Zwierzina
Holden T Maecker
Jianda Yuan
Periklis G Foukas
P2860
P2888
P3181
P356
10.1186/S40425-016-0107-3
P407
P577
2016-01-01T00:00:00Z
P5875
P6179
1025177809